ZOWALL CONSULTING HEALTH ECONOMICS & OUTCOMES RESEARCH

Zowall H, Cairns JA, Brewer C, Lamping DL, Gedroyc WMW, Regan L. Cost-effectiveness of magnetic resonance-guided ultrasound surgery for treatment of uterine fibroids. BJOG 2008 April; Volume 115, Issue 5, 653-662. (Download PDF - 231KB)

Moe Gordon W, Howlett Jonathan, Januzzi James L, Zowall H, N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure. Circulation. 2007;115:3103-3110. (Download PDF - 314KB)

Grover SA, Coupal L, Zowall H. Treating Osteoarthritis With Cyclooxygenase-2–Specific Inhibitors, What Are the Benefits of Avoiding Blood Pressure Destabilization? Hypertension. 2005;45:92. (Download PDF - 231KB)

Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS. 2004 Dec 3;18(18):2411-8. (Download PDF - 118KB).

Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: Can we save lives and money with statins? Arch Intern Med 2003;163:333-339. (Download PDF - 96KB)

Zowall H, Grover SA. Costs of dyslipidemia. Future Drugs: Expert Review of Pharmacoeconomics & Outcomes Research June 2003, Vol. 3, No. 3, Pages 273-281. (Download PDF - 203KB)

Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DRJ. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50. (Download PDF - 1200KB)

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:987-92. (Download PDF - 218KB)

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:977-83. (Download PDF - 243KB)

Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated? Circulation 2000;102:722-727. (Download PDF - 70KB)

Grover SA, Coupal L, Paquet S, Zowall H. The cost-effectiveness of HMG-CoA reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600. (Download PDF - 102KB)

Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-662. (Download PDF - 284KB)

Hamilton V, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. JAMA 1995;273(13):1032-1038. (Download PDF - 452KB)